MX2015000730A - Tratamientos terapeuticos novedosos con anticuerpos anti-her2 que tienen una fucosilacion baja. - Google Patents

Tratamientos terapeuticos novedosos con anticuerpos anti-her2 que tienen una fucosilacion baja.

Info

Publication number
MX2015000730A
MX2015000730A MX2015000730A MX2015000730A MX2015000730A MX 2015000730 A MX2015000730 A MX 2015000730A MX 2015000730 A MX2015000730 A MX 2015000730A MX 2015000730 A MX2015000730 A MX 2015000730A MX 2015000730 A MX2015000730 A MX 2015000730A
Authority
MX
Mexico
Prior art keywords
her2
her2 antibody
antibody
cancer
treatment
Prior art date
Application number
MX2015000730A
Other languages
English (en)
Spanish (es)
Inventor
Steffen Goletz
Antje Danielczyk
Original Assignee
Glycotope Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycotope Gmbh filed Critical Glycotope Gmbh
Publication of MX2015000730A publication Critical patent/MX2015000730A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX2015000730A 2012-07-18 2013-07-18 Tratamientos terapeuticos novedosos con anticuerpos anti-her2 que tienen una fucosilacion baja. MX2015000730A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261673216P 2012-07-18 2012-07-18
US201261673201P 2012-07-18 2012-07-18
US201261673229P 2012-07-18 2012-07-18
EP12197768 2012-12-18
PCT/EP2013/065189 WO2014013019A1 (en) 2012-07-18 2013-07-18 Novel therapeutic treatments with anti-her2 antibodies having a low fucosylation

Publications (1)

Publication Number Publication Date
MX2015000730A true MX2015000730A (es) 2015-08-06

Family

ID=49948317

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015000730A MX2015000730A (es) 2012-07-18 2013-07-18 Tratamientos terapeuticos novedosos con anticuerpos anti-her2 que tienen una fucosilacion baja.

Country Status (16)

Country Link
US (1) US20150166664A1 (https=)
EP (1) EP2874658A1 (https=)
JP (1) JP2015528802A (https=)
KR (1) KR20150036710A (https=)
CN (1) CN104394887A (https=)
AU (1) AU2013291964B2 (https=)
BR (1) BR112014032169A2 (https=)
CA (1) CA2875486A1 (https=)
EA (1) EA201590237A1 (https=)
IL (1) IL236714A0 (https=)
MA (1) MA37961A1 (https=)
MX (1) MX2015000730A (https=)
NZ (1) NZ701974A (https=)
SG (1) SG11201407841YA (https=)
WO (1) WO2014013019A1 (https=)
ZA (1) ZA201408938B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU92659B1 (en) * 2015-02-23 2016-08-24 Glycotope Gmbh Glycooptimized antibody drug conjugates
CN111315776A (zh) * 2017-03-29 2020-06-19 葛莱高托普有限公司 Pd-l1和ta-muc1抗体
JP7273858B2 (ja) * 2018-06-15 2023-05-15 シャンハイ ミラコーケン インコーポレイティド 癌を治療するための方法と材料
CA3112043A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
WO2020056338A1 (en) * 2018-09-14 2020-03-19 Prelude Corporation Method of selection for treatment of subjects at risk of invasive breast cancer
CN113999313A (zh) * 2020-07-28 2022-02-01 百奥泰生物制药股份有限公司 抗her2抗体及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
EP2322644A1 (en) 2000-06-28 2011-05-18 GlycoFi, Inc. Methods for producing modified glycoproteins
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
CA2481920A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Antibody composition-containing medicament
CN103540600B (zh) * 2003-01-22 2017-12-01 罗氏格黎卡特股份公司 融合构建体及其用来生产Fc受体结合亲和性和效应子功能提高的抗体的用途
FR2858235B1 (fr) 2003-07-31 2006-02-17 Lab Francais Du Fractionnement Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs
WO2005053742A1 (ja) * 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. 抗体組成物を含有する医薬
WO2005086875A2 (en) * 2004-03-11 2005-09-22 City Of Hope A humanized anti-cea t84.66 antibody and uses thereof
DOP2006000029A (es) * 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
SI2073842T1 (sl) * 2006-09-10 2015-05-29 Glycotope Gmbh Uporaba človeških celic izvirajočih iz mieloične levkemije za izražanje protiteles
WO2011044368A1 (en) * 2009-10-07 2011-04-14 Macrogenics, Inc. Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
US20120258496A1 (en) * 2010-09-27 2012-10-11 Boehringer Ingelheim International Gmbh Production of low fucose antibodies in h4-ii-e rat cells

Also Published As

Publication number Publication date
JP2015528802A (ja) 2015-10-01
SG11201407841YA (en) 2015-02-27
US20150166664A1 (en) 2015-06-18
CN104394887A (zh) 2015-03-04
BR112014032169A2 (pt) 2017-08-01
EA201590237A1 (ru) 2015-05-29
EP2874658A1 (en) 2015-05-27
AU2013291964B2 (en) 2017-12-14
WO2014013019A1 (en) 2014-01-23
ZA201408938B (en) 2016-09-28
IL236714A0 (en) 2015-02-26
CA2875486A1 (en) 2014-01-23
NZ701974A (en) 2018-03-23
AU2013291964A1 (en) 2015-02-05
KR20150036710A (ko) 2015-04-07
MA37961A1 (fr) 2016-06-30

Similar Documents

Publication Publication Date Title
AU2018278327B2 (en) Activatable anti-pdl1 antibodies and methods of use thereof
JP7046973B2 (ja) 抗ｏｘ４０抗体およびその使用
JP2022050522A (ja) 癌の治療のための併用療法
US20160068609A1 (en) Anti-cancer treatments with anti-egfr antibodies having a low fucosylation
JP7065935B2 (ja) 抗ｌｙ６ｇ６ｄ抗体及び使用方法
KR20140113912A (ko) Her3에 특이적인 결합 분자 및 이의 용도
CN110621336A (zh) 癌症治疗中抗fgfr2抗体与化学治疗剂的组合
CN114901306A (zh) 用于治疗癌症的疗法
EP3067062A1 (en) Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament
AU2013291964B2 (en) Novel therapeutic treatments with anti-HER2 antibodies having a low fucosylation
US20240317864A1 (en) B7-h4 antibody dosing regimens
CN119569881B (zh) 抗cd39抗体及其用途
WO2018182420A1 (en) Antibodies for the treatment of erbb-2/erbb-3 positive tumors
JP2024515879A (ja) 抗ｓｉｇｌｅｃ組成物及びその使用
WO2023227115A1 (en) A method of treating solid tumor
US20250282865A1 (en) COMBINATION OF ANTIBODY-DRUG CONJUGATE AND ANTI-SIRPa ANTIBODY
JP2020533278A (ja) Ｋ−Ｒａｓ遺伝子の状態に関連したＣＫ８陽性がんの治療
HK40117039A (en) Combination of antibody-drug conjugate and anti-sirpalpha antibody
CA3252302A1 (en) Combination of antibody-drug conjugate and anti-sirp.alpha. antibody
Geuijen et al. Application of unbiased combinatorial screening to generate a bispecific IgG1 that selectively and potently inhibits HER3 signaling via HER2-guided ligand blockade
CA3064588A1 (en) Activatable anti-pdl1 antibodies, and methods of use thereof